NASDAQ:SPRB Spruce Biosciences (SPRB) Stock Forecast, Price & News $2.38 -0.06 (-2.46%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$2.34▼$2.5150-Day Range$2.04▼$2.5452-Week Range$0.95▼$3.57Volume69,253 shsAverage Volume112,988 shsMarket Capitalization$96.89 millionP/E RatioN/ADividend YieldN/APrice Target$7.67 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Spruce Biosciences MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside222.1% Upside$7.67 Price TargetShort InterestHealthy0.07% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.40) to ($1.46) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.44 out of 5 starsMedical Sector203rd out of 969 stocksPharmaceutical Preparations Industry76th out of 440 stocks 4.5 Analyst's Opinion Consensus RatingSpruce Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.67, Spruce Biosciences has a forecasted upside of 222.1% from its current price of $2.38.Amount of Analyst CoverageSpruce Biosciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.07% of the outstanding shares of Spruce Biosciences have been sold short.Short Interest Ratio / Days to CoverSpruce Biosciences has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Spruce Biosciences has recently decreased by 13.97%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSpruce Biosciences does not currently pay a dividend.Dividend GrowthSpruce Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SPRB. Previous Next 0.6 News and Social Media Coverage MarketBeat Follows1 people have added Spruce Biosciences to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Spruce Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.90% of the stock of Spruce Biosciences is held by insiders.Percentage Held by Institutions78.58% of the stock of Spruce Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Spruce Biosciences are expected to decrease in the coming year, from ($1.40) to ($1.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Spruce Biosciences is -1.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Spruce Biosciences is -1.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSpruce Biosciences has a P/B Ratio of 0.82. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Spruce Biosciences (NASDAQ:SPRB) StockSpruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.Read More SPRB Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SPRB Stock News HeadlinesSeptember 15, 2023 | americanbankingnews.comSpruce Biosciences' (SPRB) "Outperform" Rating Reiterated at Royal Bank of CanadaSeptember 15, 2023 | americanbankingnews.comSpruce Biosciences' (SPRB) "Buy" Rating Reaffirmed at HC WainwrightSeptember 24, 2023 | Legacy Research (Ad)WARNING: Mandatory U.S. Dollar Recall is Weeks AwayIf you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.September 13, 2023 | markets.businessinsider.comSpruce Biosciences (SPRB) Gets a Buy from H.C. WainwrightSeptember 12, 2023 | markets.businessinsider.comJMP Securities Sticks to Their Buy Rating for Spruce Biosciences (SPRB)September 8, 2023 | msn.comSVB Leerink Upgrades Spruce Biosciences (SPRB)September 8, 2023 | markets.businessinsider.comAnalyst Ratings for Spruce BiosciencesAugust 28, 2023 | finance.yahoo.comSpruce Biosciences to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceSeptember 24, 2023 | Legacy Research (Ad)WARNING: Mandatory U.S. Dollar Recall is Weeks AwayIf you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.August 18, 2023 | msn.comHC Wainwright & Co. Reiterates Spruce Biosciences (SPRB) Buy RecommendationAugust 18, 2023 | msn.comOppenheimer Maintains Spruce Biosciences (SPRB) Outperform RecommendationAugust 18, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Bioxcel Therapeutics (BTAI), Spruce Biosciences (SPRB) and Alpha Tau Medical Ltd (DRTS)August 16, 2023 | msn.comJMP Securities Maintains Spruce Biosciences (SPRB) Outperform RecommendationAugust 16, 2023 | markets.businessinsider.comExpert Ratings for Spruce BiosciencesAugust 15, 2023 | markets.businessinsider.comJMP Securities Sticks to Its Buy Rating for Spruce Biosciences (SPRB)August 14, 2023 | finance.yahoo.comSpruce Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate UpdatesJune 13, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Spruce Biosciences (SPRB), Vaccitech Plc (VACC)June 12, 2023 | finance.yahoo.comSpruce Biosciences Announces Acceptance of Abstract for Presentation at the Annual Meeting of the Endocrine Society (ENDO 2023)May 25, 2023 | finance.yahoo.comSpruce Biosciences Appoints Percival Barretto-Ko to Board of DirectorsMay 24, 2023 | finance.yahoo.comSpruce Biosciences to Participate in the Jefferies Healthcare ConferenceMay 23, 2023 | msn.comOppenheimer Reiterates Spruce Biosciences (SPRB) Outperform RecommendationMay 22, 2023 | finance.yahoo.comSpruce Biosciences Honored at CARES Foundation 15th Annual Everyone CARES GalaMay 17, 2023 | msn.comRBC Capital Reiterates Spruce Biosciences (SPRB) Outperform RecommendationMay 16, 2023 | msn.comJMP Securities Reiterates Spruce Biosciences (SPRB) Market Outperform RecommendationMay 16, 2023 | msn.comCredit Suisse Reiterates Spruce Biosciences (SPRB) Outperform RecommendationMay 16, 2023 | markets.businessinsider.comAnalyst Expectations for Spruce Biosciences's FutureMay 16, 2023 | finance.yahoo.comInvestors in Spruce Biosciences (NASDAQ:SPRB) have seen decent returns of 63% over the past yearSee More Headlines Receive SPRB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Spruce Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address SPRB Company Calendar Last Earnings8/14/2023Today9/24/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SPRB CUSIPN/A CIK1683553 Webwww.sprucebiosciences.com Phone415-655-4168FaxN/AEmployees32Year FoundedN/APrice Target and Rating Average Stock Price Forecast$7.67 High Stock Price Forecast$10.00 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+222.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-46,180,000.00 Net MarginsN/A Pretax Margin-1,166.41% Return on Equity-54.80% Return on Assets-43.19% Debt Debt-to-Equity Ratio0.03 Current Ratio5.46 Quick Ratio5.46 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.90 per share Price / Book0.82Miscellaneous Outstanding Shares40,710,000Free Float38,309,000Market Cap$96.89 million OptionableNot Optionable Beta2.13 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Michael G. Grey (Age 70)Exec. Chairman Comp: $70kDr. Javier Szwarcberg M.D. (Age 53)M.P.H., CEO & Director Comp: $693.9kMr. Samir M. Gharib CPA (Age 41)CPA, M.B.A., Pres & CFO Comp: $536.13kDr. Ralph William Charlton III (Age 53)M.D., Chief Medical Officer Comp: $436.38kMs. P. J. RamtinSr. VP of Bus. OperationsMs. Heidi Petersen M.P.H.Sr. VP of Regulatory & QualityMore ExecutivesKey CompetitorsAtossa TherapeuticsNASDAQ:ATOSAnnovis BioNYSE:ANVSNGM BiopharmaceuticalsNASDAQ:NGMMilestone PharmaceuticalsNASDAQ:MISTLumiraDxNASDAQ:LMDXView All CompetitorsInstitutional OwnershipWorth Venture Partners LLCBought 7,000 shares on 8/15/2023Ownership: 0.698%Citadel Advisors LLCSold 1,627,341 shares on 8/15/2023Ownership: 0.179%State Street CorpSold 34,307 shares on 8/14/2023Ownership: 0.148%Northern Trust CorpBought 43,356 shares on 8/11/2023Ownership: 0.144%JPMorgan Chase & Co.Sold 34,619 shares on 8/11/2023Ownership: 0.059%View All Institutional Transactions SPRB Stock - Frequently Asked Questions Should I buy or sell Spruce Biosciences stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spruce Biosciences in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SPRB shares. View SPRB analyst ratings or view top-rated stocks. What is Spruce Biosciences' stock price forecast for 2023? 6 Wall Street analysts have issued 12 month price targets for Spruce Biosciences' stock. Their SPRB share price forecasts range from $4.00 to $10.00. On average, they anticipate the company's stock price to reach $7.67 in the next twelve months. This suggests a possible upside of 222.1% from the stock's current price. View analysts price targets for SPRB or view top-rated stocks among Wall Street analysts. How have SPRB shares performed in 2023? Spruce Biosciences' stock was trading at $1.0974 at the beginning of the year. Since then, SPRB shares have increased by 116.9% and is now trading at $2.38. View the best growth stocks for 2023 here. When is Spruce Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our SPRB earnings forecast. How were Spruce Biosciences' earnings last quarter? Spruce Biosciences, Inc. (NASDAQ:SPRB) released its quarterly earnings data on Monday, August, 14th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.05. The business earned $2.17 million during the quarter, compared to analyst estimates of $2.45 million. When did Spruce Biosciences IPO? (SPRB) raised $75 million in an initial public offering on Friday, October 9th 2020. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and RBC Capital Markets acted as the underwriters for the IPO. What is Spruce Biosciences' stock symbol? Spruce Biosciences trades on the NASDAQ under the ticker symbol "SPRB." Who are Spruce Biosciences' major shareholders? Spruce Biosciences' stock is owned by many different institutional and retail investors. Top institutional investors include Worth Venture Partners LLC (0.70%), BlackRock Inc. (0.66%), Renaissance Technologies LLC (0.60%), Geode Capital Management LLC (0.55%), Citadel Advisors LLC (0.18%) and State Street Corp (0.15%). Insiders that own company stock include Bali Muralidhar, Camilla V Simpson, Holdings A/S Novo and Venture Fund Iii L Rivervest. View institutional ownership trends. How do I buy shares of Spruce Biosciences? Shares of SPRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Spruce Biosciences' stock price today? One share of SPRB stock can currently be purchased for approximately $2.38. How much money does Spruce Biosciences make? Spruce Biosciences (NASDAQ:SPRB) has a market capitalization of $96.89 million. The company earns $-46,180,000.00 in net income (profit) each year or ($1.67) on an earnings per share basis. How can I contact Spruce Biosciences? The official website for the company is www.sprucebiosciences.com. The company can be reached via phone at 415-655-4168 or via email at investors@sprucebiosciences.com. This page (NASDAQ:SPRB) was last updated on 9/24/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spruce Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.